STRIVE-2 MRI-Defined Brain Frailty and Functional Outcomes After Thrombectomy: A Multicenter Study.
TL;DR
It is suggested that while CSVD assessment improves post-thrombectomy prognostication, it should not be used as a criterion to preclude patients from MT eligibility and cumulative total CSVD burden acts as a strong, dose-dependent predictor of functional outcomes and symptomatic hemorrhage.
Abstract
Background
AND
Objectives
Mechanical thrombectomy (MT) is the standard of care for large vessel occlusion (LVO) stroke, yet nearly half of patients fail to achieve functional independence. Cerebral small vessel disease (CSVD) represents a marker of brain frailty that may impair recovery. We aimed to evaluate whether comprehensive MRI-defined CSVD markers before MT predict 90-day functional outcomes and hemorrhagic transformation.
Methods
This retrospective, multicenter cohort study analyzed consecutive patients with anterior circulation LVO treated with MT (2015-2022) at two tertiary centers. CSVD markers (white matter hyperintensities [WMH], lacunes, cerebral microbleeds [CMBs], enlarged perivascular spaces [EPVS], and brain atrophy) were assessed on pre-treatment MRI according to STRIVE-2 criteria. The primary outcome was functional dependence or death at 90 days (modified Rankin Scale [mRS] score 3-6). Bayesian logistic regression models estimated odds ratios (aOR) and 95% credible intervals (CrI), adjusting for age, sex, thrombolysis, infarct volume, time-to-puncture and reperfusion status. A composite CSVD score including all 5 markers was also evaluated.
Results
Among 479 patients (median age 72 years [IQR 59-80]; 46% female), successful reperfusion (mTICI 2b-3) was achieved in 83% and 47% had 90-day mRS 3-6. Functional dependence was independently associated with the presence of lacunes (aOR 2.07; 95% CrI 1.22-3.59; posterior probability [PP] >99%), moderate-to-severe brain atrophy (aOR 1.92; 95% CrI 1.09-3.40; PP 99%), and moderate-to-severe WMH (aOR 1.63; 95% CrI 0.94-2.84; PP 96%). Furthermore, every 1-point increase in the 5-item composite CSVD score demonstrated a dose-dependent increase in the odds of functional dependence (aOR 1.44; 95% CrI 1.23-1.69; PP >99%) and SICH (aOR 1.33; 95% CrI 0.92-1.93; PP 94%).
Discussion
Preexisting lacunes, atrophy, and WMH are independent determinants of worse functional recovery after MT. Importantly, cumulative total CSVD burden acts as a strong, dose-dependent predictor of functional outcomes and symptomatic hemorrhage. These findings suggest that while CSVD assessment improves post-thrombectomy prognostication, it should not be used as a criterion to preclude patients from MT eligibility.